Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Merck (NYSE:MRK) with a Market Perform ...

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

The company’s monoclonal antibody met primary endpoints in Phase IIb/III trial in infants entering their first respiratory ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

From manufacturing vital drugs to driving research to raising funds and awareness, leaders like AstraZeneca, Ford and Estée Lauder are having an impact ...

CVS announced Friday that CEO Karen Lynch will be replaced by David Joyner, as consumer spending drops at the company's retail pharmacies and Aetna, its insurance unit, faces higher medical costs.